Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

HPV-related cancers

Clinical and regulatory intelligence for HPV-related cancers with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
0
Assets
3

Relevant assets

Advancements →
HPV →
Oncology →

Relevant companies

Moderna →

Recent signals(4)

ClinicalJuly 11, 2026

Advancements and Challenges in HPV Vaccine Development for Cancer Treatment

The review highlights significant progress in HPV vaccine development while addressing challenges like type replacement and the need for gender-inclusive vaccination.

ClinicalJuly 9, 2026

HPV Vaccination Shows High Efficacy Against Cancer and Precancer Outcomes

HPV vaccination demonstrates 99% efficacy against HPV16/18 infection and significant reductions in cervical cancer rates.

StrategyJune 21, 2026

HPV-associated cancers impose significant burden on Peruvian men, highlighting need for vaccination and early diagnosis

HPV-associated cancers in Peruvian men resulted in 5,996 outpatient consultations and 1,136 hospitalizations from 2015-2019, with a significant number of deaths attributable to HPV.

ClinicalJune 17, 2026

E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

The study demonstrates that the HPV16 E7 mRNA/LNP vaccine induces strong immune responses and tumor regression in early-stage HPV tumors in mice.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

HPV-related cancers →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.